Education
About Us
Working with TipRanks
Follow Us
Japan Tissue Engineering Co., Ltd. (JP:7774)
:7774
7774 Stock Chart & Stats
¥575.00
¥0.00(0.00%)
At close: 4:00 PM EST
¥575.00
¥0.00(0.00%)
Day’s Range― - ―
52-Week Range¥361.00 - ¥883.00
Previous CloseN/A
Volume17.40K
Average Volume (3M)51.90K
Market Cap
¥29.69B
Enterprise Value¥26.03B
Total Cash (Recent Filing)¥3.92B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta0.99
Next Earnings
May 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.56
Shares Outstanding40,610,200
10 Day Avg. Volume45,190
30 Day Avg. Volume51,896
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)3.19
Price to Sales (P/S)7.56
P/FCF Ratio-82.67
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Very Low Debt / Strong Balance SheetA near-zero debt profile provides durable financial flexibility for a capital-intensive biotech: it lowers bankruptcy risk, preserves headroom for clinical and commercial investments, and reduces refinancing pressure while the company pursues revenue scaling and product rollouts.
Rapid Revenue GrowthStrong, recurring top-line growth indicates improving commercial traction for approved cell therapy products and services. Persistent revenue expansion supports scale economies, capacity utilization, and the potential to convert gross-margin strength into sustainable operating profits if cost discipline follows.
Commercialized Products Plus CDMO ServicesOwning approved regenerative therapies while offering CDMO-like services creates diversified, structurally durable revenue streams. The combined product sales and service model leverages regulatory/compliance expertise and creates higher switching costs for customers, supporting repeat business.
Bears Say
Negative Operating And Free Cash FlowPersistent cash burn undermines self-funding capacity; ongoing negative operating and free cash flow raise the probability of external financing needs. That can dilute shareholders, impose funding timing risk for R&D/clinical programs, and constrain long-term scaling plans.
Return To Losses In FY2025Reverting from profitability to material losses signals execution or cost-control challenges. This volatility complicates multi-year planning, reduces retained-earnings capacity to fund growth, and increases reliance on external capital if profitability is not sustainably restored.
Operating Costs Pressure MarginsHigh gross margins are offset by elevated operating expenses, suggesting fixed-cost intensity or inefficient overhead. Until operating leverage is realized, margin volatility will persist, slowing the translation of revenue gains into durable net income and free cash flow.
Japan Tissue Engineering Co., Ltd. News
7774 FAQ
What was Japan Tissue Engineering Co., Ltd.’s price range in the past 12 months?
Japan Tissue Engineering Co., Ltd. lowest stock price was ¥361.00 and its highest was ¥883.00 in the past 12 months.
What is Japan Tissue Engineering Co., Ltd.’s market cap?
Japan Tissue Engineering Co., Ltd.’s market cap is ¥29.69B.
When is Japan Tissue Engineering Co., Ltd.’s upcoming earnings report date?
Japan Tissue Engineering Co., Ltd.’s upcoming earnings report date is May 01, 2026 which is in 54 days.
How were Japan Tissue Engineering Co., Ltd.’s earnings last quarter?
Japan Tissue Engineering Co., Ltd. released its earnings results on Jan 30, 2026. The company reported -¥4.56 earnings per share for the quarter, missing the consensus estimate of N/A by -¥4.56.
Is Japan Tissue Engineering Co., Ltd. overvalued?
According to Wall Street analysts Japan Tissue Engineering Co., Ltd.’s price is currently Overvalued.
Does Japan Tissue Engineering Co., Ltd. pay dividends?
Japan Tissue Engineering Co., Ltd. does not currently pay dividends.
What is Japan Tissue Engineering Co., Ltd.’s EPS estimate?
Japan Tissue Engineering Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Japan Tissue Engineering Co., Ltd. have?
Japan Tissue Engineering Co., Ltd. has 40,610,200 shares outstanding.
What happened to Japan Tissue Engineering Co., Ltd.’s price movement after its last earnings report?
Japan Tissue Engineering Co., Ltd. reported an EPS of -¥4.56 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.255%.
Which hedge fund is a major shareholder of Japan Tissue Engineering Co., Ltd.?
Currently, no hedge funds are holding shares in JP:7774
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Japan Tissue Engineering Co., Ltd.
Japan Tissue Engineering Co., Ltd. engages in the regenerative medicine business in Japan. The company operates through Regenerative Medicine Product, Regenerative Medicine Outsourcing, and Research and Development Support segments. It offers autologous cultured epidermis, cartilage, corneal epithelium, and oral mucosal epithelium to medical institutions for the purpose of medical treatment. The company also provides tissue-engineered medical products. In addition, it researches and develops human 3-dimensional cultured tissue models for use in the development of cosmetics and drugs for external use, as well as in research that employs skin and cornea tissues. Further, the company offers regenerative medicine contract development and manufacturing services. The company was founded in 1999 and is headquartered in Gamagori, Japan. Japan Tissue Engineering Co., Ltd. is a subsidiary of Teijin Limited.